A review of the device history record (dhr) was conducted which confirmed that the product met all quality criteria and manufacturing specifications prior to release.
There is no information to indicate that a malfunction occurred.
The instructions for use warn that the device must be used under the prescription of a physician.
The nxstage user guide and instructions for use include allergic reaction as a potential risk associated with dialysis therapy and also include warnings to monitor for potential allergic reactions.
The patient¿s blood pressure, vital signs, general well-being, and physical status should be monitored closely throughout the treatment.
Biocompatability has been established.
|
A report was received on 23 nov 2020 from the nurse of a (b)(6) year old female with a medical history including diabetes, hypertension, hyperlipidemia and end stage renal disease, who stated the patient experienced an allergic reaction during their first hemodialysis treatment with the device on (b)(6) 2020.
Additional information was received on 01 dec 2020 from the nurse who stated approximately thirty minutes into treatment on (b)(6) 2020 the patient experienced swelling of her eyes and face.
50mg of diphenhydramine was administered intravenously, oxygen was applied via nasal canula and the patient was transported to the emergency room.
Following the event the patient recovered without sequelae and has changed to an unspecified device from a different manufacturer.
|